- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:26 | Boehringer's Jascayd gains NMPA approval for idiopathic pulmonary fibrosis | ||
| Mi | Portal Therapeutics receives FDA orphan, fast track designations for PORT-77 | ||
| Di | Citius Oncology finalises McKesson deal for Lymphir distribution | ||
| Fr | Tempus partners with Whitehawk on oncology research | ||
| 16.10. | FDA accepts Chiesi triple combination inhaler application for asthma | ||
| 15.10. | iQure, University of Padova collaborate to investigate iQ-007 mechanism | ||
| 14.10. | US FDA grants BeOne's sonrotoclax breakthrough designation for MCL | ||
| 13.10. | Adcendo receives FDA fast track status for ADCE-D01 to treat STS | ||
| 10.10. | Bio-Thera, Intas extend partnership for golimumab biosimilar | ||
| 09.10. | Nilo Therapeutics raises $101m to develop neural circuit therapies | ||
| 08.10. | AeroRx secures $21m for nebulised COPD treatment development | ||
| 07.10. | FDA accepts priority review for Orca Bio's hematological malignancy therapy | ||
| 06.10. | FDA fast-tracks Alto Neuroscience's ALTO-101 for CIAS treatment | ||
| 01.10. | FDA approves Novartis' Rhapsido for CSU treatment | ||
| 30.09. | BioLineRx partners with Hemispherian to advance brain cancer therapy | ||
| 29.09. | AbbVie files NDA with FDA for tavapadon to treat Parkinson's disease | ||
| 26.09. | Lilly secures EC approval for Kisunla to treat Alzheimer's disease | ||
| 25.09. | Sandoz launches generic iron sucrose injection in US market | ||
| 24.09. | Leqembi approved in Australia to treat early Alzheimer's | ||
| 23.09. | Avenzo Therapeutics secures $60m in series B funding for oncology therapies | ||
| 22.09. | J&J's Tremfya gets FDA approval for SC induction in active UC | ||
| 19.09. | Biogen to acquire Alcyone Therapeutics for $85m | ||
| 18.09. | Deciphera's Romvimza secures EC nod for TGCT treatment | ||
| 17.09. | Dualitas secures $65m for bispecific antibody pipeline | ||
| 16.09. | Argo Biopharma secures NMPA clearance for Phase II PNH trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .